Skip to content

Clinical Characterization of Symptomatic Populations

Clinical Characterization of Symptomatic Populations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03319212
Enrollment
105
Registered
2017-10-24
Start date
2017-09-29
Completion date
2018-08-15
Last updated
2019-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ametropia

Brief summary

This is an unmasked, non-randomized, single arm, stratified, dispensing investigation of symptomatic and asymptomatic subject populations. Subjects will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.

Interventions

Senofilcon A Daily Disposable Contact Lenses

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Between 18 and 55 (inclusive) years of age at the time of screening. 4. Be a current soft contact lens wearer in both eyes with a minimum of 3 days/week wear time over the last 1 month by self-report. 5. Have a baseline CLDEQ-8 score of either: 1. 7 or lower 2. 15 or greater 6. Subjects must possess a functional / usable pair of spectacles and bring them to the visit (only if applicable - to the investigators discretion). 7. Subjects must pass a pre-screening questionnaire. 8. Subjects must be willing to discontinue all contact lens wear for approximately 1 week/ 9. Subjects must present to visit 1 with their habitual lenses on eye for at least 6 hours.

Exclusion criteria

* Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. Currently pregnant or lactating, by self-report. 2. Any ocular or systemic allergies, disease or use of medication which may interfere with contact lens wear (at the discretion of the investigator). 3. Any active ocular abnormalities/conditions that may interfere with contact lens wear (at the discretion of the investigator). 4. Any infectious diseases (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV), by self-report. 5. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. 6. Habitual contact lens wear modality as extended wear (≥1 night per month of extended wear). 7. Habitual contact lens is rigid gas permeable, toric, monovision or multi-focal 8. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.) 9. Participation in any contact lens or lens care product clinical trial within 2 weeks prior to study enrollment. 10. Employee or employee's immediate family member of clinical site (e.g., Investigator, Coordinator, Technician). 11. Current habitual use of Restasis, Xiidra, ocular steroids, or any medication (RX or OTC) that may interfere with contact lens wear (at the discretion of the investigator).

Design outcomes

Primary

MeasureTime frameDescription
Meibomian Gland Imaging4-Week Follow-upMeibomian gland imaging was assessed in each each subject eye, at baseline, 4-Week Follow-up (during lens wear) and the the 5-Week Follow-up on subjects' bare eyes. Meibomian gland imaging is expressed interms of area of loss using the following grading scale: Degree 0 ≈ 0%; Degree 1 ≤ 25%; Degree 2 26% - 50%; Degree 3 51% - 75%; Degree 4 ≥ 75%.
Meibomian Gland Expressibility4-Week Follow-upMeibomian glands were assessed in the three regions of each lower eyelid: temporal, central, and nasal. Approximately five glands are expressed per region with each use of the Meibomian Gland Evaluator. Secretions for each of the 5 glands selected within the three regions were graded using the following secretion grading scale: Grade 0 = No Secretion (Includes capped orifices), Grade 1 = Inspissated (semi-solid, toothpaste-like consistency), Grade 2 = Colored/Cloudy Liquid, Grade 3 = Clear Liquid Oil. The total grades for 5 glands per region was calculated for each subject. The total Meibomian Gland Secretion Score was calculated by adding the grades for the 15 glands assessed. Mean and standard deviation for total grade per region and total Meibomian Gland Secretion Score were reported for each stratum. Total scores range from 0 to 15 were lower score indicate worsening meibomian gland expressability.
Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings4-Week Follow-upLid margin evaluation was conducted for upper and lower lids for both left and right eyes. The presence of the following biomicroscopy findings were recorded as No/normal or Yes/abnormal: * Irregularity: Notching of Margin * Vascularity of Lid Margin: Telangiectasia * Meibomian Gland Pouting, Plugging, or Capping * Lid/Lash Margin Debris Findings. The number of positive findings (yes) was reported for each group.
Lid Wiper Epitheliopathy4-Week Follow-upHorizontal length of staining and sagittal width of staining were graded for both upper and lower lids for each eye. Average grade was calculated separately for upper and lower lids, and the final grade was calculated as the average grade across upper and lower lids. Mean and standard deviation were reported for the final grade by stratum. Subjects were classified according to their final lid wiper epitheliopathy grade for each eye using the following scale: None = 0, Mild = 0.25 - 1.00, Moderate = 1.25 - 2.00, and Severe = 2.25 - 3.00. Final Grades range from 0 to 3, where higher final grades indicate worsening lid wiper epitheliopathy.
Conjunctival Folds4-Week Follow-upLid-parallel conjunctival folds (LIPCOF) will be evaluated in the area perpendicular to the temporal and nasal limbus on the bulbar conjunctiva above the lower lid (temporal and nasal LIPCOF, respectively), and classified using the LIPCOF grading scale: 0 = No conjunctival folds, 1 = One permanent and clear parallel fold, 2 = Two permanent and clear parallel folds (normally lower than 0.2mm), and 3 = More than two permanent and clear parallel folds (normally higher than 0.2mm).

Secondary

MeasureTime frameDescription
Conjunctival Redness4-Week Follow-upLimbal and bulbar conjunctival redness were assessed or each quadrant (nasal, temporal, inferior, superior) using the following scale: 0 = Normal, 1 = Trace, 2 = Mild, 3 = Moderate, and 4 = Severe.
Tear Film Lipid Pattern4-Week Follow-upTear film lipid pattern was recorded for each eye using the following categories: None, Open Meshwork, Closed (Tight Meshwork), Flow (Wave), Amorphous, Colors, and Other.
Conjunctival Staining4-Week Follow-upConjunctival staining was assessed for each eye by quadrant (Superior, Inferior, Nasal, Temporal) utilizing the following scale: Grade 0 = None (No conjunctival staining), Grade 1 = Trace (Scattered superficial punctate staining), Grade 2 = Mild (Regional or generalized punctate staining), Grade 3 = Moderate (Significant coalesced punctate staining), Grade 4 = Severe (Patch staining).
Corneal Staining4-Week Follow-upCorneal staining was assessed for each eye by region (Central, Superior, Inferior, Nasal, Temporal). Corneal staining type was evaluated using the following the scale: Grade 0 = None, Grade 1 = Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate, and Grade 4 = Patch (\>1mm). Corneal staining area was evaluated using the following the scale: Grade 0 = 0% of region covered, Grade 1 = 10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4 = 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered, Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered, and Grade 10 = 100% of region covered. The following scale was used in the grading of corneal staining depth: Grade 0 = None, Grade 0 = Superficial epithelial, Grade 2 = Full epithelial, and Grade 3 = Stromal glow.
Tear Film Lipid Layer Thickness4-Week Follow-upTear film lipid layer thickness was measured for each eye using LipiView II. The Review Lipid Images screen provided numerical analysis of the measured lipid layer thickness in nanometers (nm) from 10 (thinnest) to 240 (thickest), with a precision of 1 nm and an accuracy of 10 nm.
Tear Film Stability4-Week Follow-upNon-invasive tear break-up time (NIBUT) was measured for each eye to indicate the stability of the tear film. NIBUT is measured as the time interval in seconds after the final blink to the first appearance of distortion in the reflected rings; or to the time that the participant has to blink due to discomfort. Three measurements were taken on each eye. The average NIBUT was reported for each group.

Countries

Canada, United States

Participant flow

Recruitment details

A total of 105 subjects were enrolled into this study. Of those enrolled 81, were dispensed a study lens while 24 subjects failed to meet all eligibility criteria. Of those dispensed a study lens, 73 completed the study while 8 subjects were discontinued. All subjects were disepsned the same study lens senofilcon A.

Pre-assignment details

Subjects were stratified into two subject groups: symptomatic (baseline CLDEQ-8 score of 15 or greater) and asymptomatic (baseline CLDEQ-8 score of 7 or lower).

Participants by arm

ArmCount
Asymptomatic
Subjects with baseline CLDEQ-8 score of 7 or lower were assigned to the asymptomatic group throughout the entire duration of the study
29
Symptomatic
Subjects with baseline CLDEQ-8 score of 15 or greater were assigned to the symptomatic group throughout the entire duration of the study.
52
Total81

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyAdverse Event22
Overall StudyDiscontinued as moving out of local area01
Overall StudyLost to Follow-up01
Overall StudyPhysician Decision10
Overall StudyWithdrawal by Subject01

Baseline characteristics

CharacteristicAsymptomaticSymptomaticTotal
Age, Continuous28.76 Years
STANDARD_DEVIATION 7.229
28.17 Years
STANDARD_DEVIATION 9.096
28.38 Years
STANDARD_DEVIATION 8.4333
Race/Ethnicity, Customized
Asian
7 Participants20 Participants27 Participants
Race/Ethnicity, Customized
Black or African American
1 Participants2 Participants3 Participants
Race/Ethnicity, Customized
Other
0 Participants3 Participants3 Participants
Race/Ethnicity, Customized
White
21 Participants27 Participants48 Participants
Region of Enrollment
Canada
18 Participants38 Participants56 Participants
Region of Enrollment
United States
11 Participants14 Participants25 Participants
Sex: Female, Male
Female
18 Participants36 Participants54 Participants
Sex: Female, Male
Male
11 Participants16 Participants27 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 81
other
Total, other adverse events
0 / 81
serious
Total, serious adverse events
0 / 81

Outcome results

Primary

Conjunctival Folds

Lid-parallel conjunctival folds (LIPCOF) will be evaluated in the area perpendicular to the temporal and nasal limbus on the bulbar conjunctiva above the lower lid (temporal and nasal LIPCOF, respectively), and classified using the LIPCOF grading scale: 0 = No conjunctival folds, 1 = One permanent and clear parallel fold, 2 = Two permanent and clear parallel folds (normally lower than 0.2mm), and 3 = More than two permanent and clear parallel folds (normally higher than 0.2mm).

Time frame: 4-Week Follow-up

Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.

ArmMeasureGroupValue (NUMBER)
AsymptomaticConjunctival FoldsTemporal- Grade 027 eyes
AsymptomaticConjunctival FoldsTemporal- Grade 122 eyes
AsymptomaticConjunctival FoldsTemporal- Grade 23 eyes
AsymptomaticConjunctival FoldsTemporal- Grade 30 eyes
AsymptomaticConjunctival FoldsNasal- Grade 043 eyes
AsymptomaticConjunctival FoldsNasal- Grade 19 eyes
AsymptomaticConjunctival FoldsNasal- Grade 20 eyes
AsymptomaticConjunctival FoldsNasal- Grade 30 eyes
SymptomaticConjunctival FoldsNasal- Grade 30 eyes
SymptomaticConjunctival FoldsTemporal- Grade 045 eyes
SymptomaticConjunctival FoldsNasal- Grade 055 eyes
SymptomaticConjunctival FoldsTemporal- Grade 141 eyes
SymptomaticConjunctival FoldsNasal- Grade 29 eyes
SymptomaticConjunctival FoldsTemporal- Grade 28 eyes
SymptomaticConjunctival FoldsNasal- Grade 130 eyes
SymptomaticConjunctival FoldsTemporal- Grade 30 eyes
Primary

Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings

Lid margin evaluation was conducted for upper and lower lids for both left and right eyes. The presence of the following biomicroscopy findings were recorded as No/normal or Yes/abnormal: * Irregularity: Notching of Margin * Vascularity of Lid Margin: Telangiectasia * Meibomian Gland Pouting, Plugging, or Capping * Lid/Lash Margin Debris Findings. The number of positive findings (yes) was reported for each group.

Time frame: 4-Week Follow-up

Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.

ArmMeasureGroupValue (NUMBER)
AsymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsIrregularity: Notching of Margin1 Number of eyes
AsymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsVascularity of Lid Margin: Telangiectasia12 Number of eyes
AsymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsMeibomian Gland Pouting, Plugging, or Capping12 Number of eyes
AsymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsLid/Lash Margin Debris Findings0 Number of eyes
SymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsLid/Lash Margin Debris Findings10 Number of eyes
SymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsIrregularity: Notching of Margin5 Number of eyes
SymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsMeibomian Gland Pouting, Plugging, or Capping33 Number of eyes
SymptomaticLid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy FindingsVascularity of Lid Margin: Telangiectasia21 Number of eyes
Primary

Lid Wiper Epitheliopathy

Horizontal length of staining and sagittal width of staining were graded for both upper and lower lids for each eye. Average grade was calculated separately for upper and lower lids, and the final grade was calculated as the average grade across upper and lower lids. Mean and standard deviation were reported for the final grade by stratum. Subjects were classified according to their final lid wiper epitheliopathy grade for each eye using the following scale: None = 0, Mild = 0.25 - 1.00, Moderate = 1.25 - 2.00, and Severe = 2.25 - 3.00. Final Grades range from 0 to 3, where higher final grades indicate worsening lid wiper epitheliopathy.

Time frame: 4-Week Follow-up

Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.

ArmMeasureValue (MEAN)Dispersion
AsymptomaticLid Wiper Epitheliopathy0.50 Units on a scaleStandard Deviation 0.718
SymptomaticLid Wiper Epitheliopathy0.28 Units on a scaleStandard Deviation 0.489
Primary

Meibomian Gland Expressibility

Meibomian glands were assessed in the three regions of each lower eyelid: temporal, central, and nasal. Approximately five glands are expressed per region with each use of the Meibomian Gland Evaluator. Secretions for each of the 5 glands selected within the three regions were graded using the following secretion grading scale: Grade 0 = No Secretion (Includes capped orifices), Grade 1 = Inspissated (semi-solid, toothpaste-like consistency), Grade 2 = Colored/Cloudy Liquid, Grade 3 = Clear Liquid Oil. The total grades for 5 glands per region was calculated for each subject. The total Meibomian Gland Secretion Score was calculated by adding the grades for the 15 glands assessed. Mean and standard deviation for total grade per region and total Meibomian Gland Secretion Score were reported for each stratum. Total scores range from 0 to 15 were lower score indicate worsening meibomian gland expressability.

Time frame: 4-Week Follow-up

Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.

ArmMeasureGroupValue (MEAN)Dispersion
AsymptomaticMeibomian Gland ExpressibilityCentral Lower Lid9.04 Score on a ScaleStandard Deviation 5.068
AsymptomaticMeibomian Gland ExpressibilityTemporal Lower Lid8.71 Score on a ScaleStandard Deviation 4.795
AsymptomaticMeibomian Gland ExpressibilityNasal Lower Lid7.94 Score on a ScaleStandard Deviation 4.976
AsymptomaticMeibomian Gland ExpressibilityTotal Score25.69 Score on a ScaleStandard Deviation 13.964
SymptomaticMeibomian Gland ExpressibilityTotal Score22.55 Score on a ScaleStandard Deviation 12.649
SymptomaticMeibomian Gland ExpressibilityCentral Lower Lid8.07 Score on a ScaleStandard Deviation 5.055
SymptomaticMeibomian Gland ExpressibilityNasal Lower Lid6.54 Score on a ScaleStandard Deviation 4.571
SymptomaticMeibomian Gland ExpressibilityTemporal Lower Lid7.94 Score on a ScaleStandard Deviation 4.803
Primary

Meibomian Gland Imaging

Meibomian gland imaging was assessed in each each subject eye, at baseline, 4-Week Follow-up (during lens wear) and the the 5-Week Follow-up on subjects' bare eyes. Meibomian gland imaging is expressed interms of area of loss using the following grading scale: Degree 0 ≈ 0%; Degree 1 ≤ 25%; Degree 2 26% - 50%; Degree 3 51% - 75%; Degree 4 ≥ 75%.

Time frame: 4-Week Follow-up

Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.

ArmMeasureGroupValue (NUMBER)
AsymptomaticMeibomian Gland ImagingDegree 010 eyes
AsymptomaticMeibomian Gland ImagingDegree 123 eyes
AsymptomaticMeibomian Gland ImagingDegree 218 eyes
AsymptomaticMeibomian Gland ImagingDegree 31 eyes
SymptomaticMeibomian Gland ImagingDegree 38 eyes
SymptomaticMeibomian Gland ImagingDegree 04 eyes
SymptomaticMeibomian Gland ImagingDegree 216 eyes
SymptomaticMeibomian Gland ImagingDegree 166 eyes
Secondary

Conjunctival Redness

Limbal and bulbar conjunctival redness were assessed or each quadrant (nasal, temporal, inferior, superior) using the following scale: 0 = Normal, 1 = Trace, 2 = Mild, 3 = Moderate, and 4 = Severe.

Time frame: 4-Week Follow-up

Population: All subjects dispensed a study lens.

ArmMeasureGroupValue (NUMBER)
AsymptomaticConjunctival RednessBulbar-Superior- Grade 30 eyes
AsymptomaticConjunctival RednessBulbar-Temporal- Grade 013 eyes
AsymptomaticConjunctival RednessBulbar-Superior- Grade 40 eyes
AsymptomaticConjunctival RednessBulbar-Inferior-Grade 20 eyes
AsymptomaticConjunctival RednessLimbal-Nasal- Grade 026 eyes
AsymptomaticConjunctival RednessBulbar-Nasal- Grade 012 eyes
AsymptomaticConjunctival RednessLimbal-Nasal- Grade 125 eyes
AsymptomaticConjunctival RednessLimbal-Nasal- Grade 23 eyes
AsymptomaticConjunctival RednessBulbar-Temporal- Grade 137 eyes
AsymptomaticConjunctival RednessLimbal-Nasal- Grade 30 eyes
AsymptomaticConjunctival RednessLimbal-Temporal- Grade 40 eyes
AsymptomaticConjunctival RednessLimbal-Nasal- Grade 40 eyes
AsymptomaticConjunctival RednessBulbar-Temporal- Grade 24 eyes
AsymptomaticConjunctival RednessLimbal-Temporal- Grade 024 eyes
AsymptomaticConjunctival RednessBulbar-Nasal- Grade 136 eyes
AsymptomaticConjunctival RednessLimbal-Temporal- Grade 128 eyes
AsymptomaticConjunctival RednessBulbar-Temporal- Grade 30 eyes
AsymptomaticConjunctival RednessLimbal-Temporal- Grade 22 eyes
AsymptomaticConjunctival RednessBulbar-Inferior-Grade 40 eyes
AsymptomaticConjunctival RednessLimbal-Temporal- Grade 30 eyes
AsymptomaticConjunctival RednessBulbar-Temporal- Grade 40 eyes
AsymptomaticConjunctival RednessBulbar-Nasal- Grade 26 eyes
AsymptomaticConjunctival RednessLimbal-Inferior- Grade 127 eyes
AsymptomaticConjunctival RednessBulbar-Inferior-Grade 023 eyes
AsymptomaticConjunctival RednessLimbal-Inferior- Grade 20 eyes
AsymptomaticConjunctival RednessLimbal-Inferior- Grade 027 eyes
AsymptomaticConjunctival RednessLimbal-Inferior- Grade 30 eyes
AsymptomaticConjunctival RednessBulbar-Nasal- Grade 30 eyes
AsymptomaticConjunctival RednessLimbal-Inferior- Grade 40 eyes
AsymptomaticConjunctival RednessBulbar-Superior- Grade 023 eyes
AsymptomaticConjunctival RednessLimbal-Superior- Grade 025 eyes
AsymptomaticConjunctival RednessBulbar-Inferior-Grade 131 eyes
AsymptomaticConjunctival RednessLimbal-Superior- Grade 129 eyes
AsymptomaticConjunctival RednessLimbal-Superior- Grade 20 eyes
AsymptomaticConjunctival RednessBulbar-Superior- Grade 130 eyes
AsymptomaticConjunctival RednessLimbal-Superior- Grade 30 eyes
AsymptomaticConjunctival RednessBulbar-Nasal- Grade 40 eyes
AsymptomaticConjunctival RednessLimbal-Superior- Grade 40 eyes
AsymptomaticConjunctival RednessBulbar-Superior- Grade 21 eyes
AsymptomaticConjunctival RednessBulbar-Inferior-Grade 30 eyes
SymptomaticConjunctival RednessLimbal-Superior- Grade 145 eyes
SymptomaticConjunctival RednessBulbar-Inferior-Grade 30 eyes
SymptomaticConjunctival RednessLimbal-Nasal- Grade 166 eyes
SymptomaticConjunctival RednessLimbal-Temporal- Grade 40 eyes
SymptomaticConjunctival RednessBulbar-Inferior-Grade 166 eyes
SymptomaticConjunctival RednessBulbar-Nasal- Grade 011 eyes
SymptomaticConjunctival RednessBulbar-Nasal- Grade 172 eyes
SymptomaticConjunctival RednessBulbar-Nasal- Grade 213 eyes
SymptomaticConjunctival RednessBulbar-Nasal- Grade 30 eyes
SymptomaticConjunctival RednessBulbar-Nasal- Grade 40 eyes
SymptomaticConjunctival RednessBulbar-Temporal- Grade 012 eyes
SymptomaticConjunctival RednessBulbar-Temporal- Grade 173 eyes
SymptomaticConjunctival RednessBulbar-Temporal- Grade 211 eyes
SymptomaticConjunctival RednessBulbar-Temporal- Grade 30 eyes
SymptomaticConjunctival RednessBulbar-Temporal- Grade 40 eyes
SymptomaticConjunctival RednessBulbar-Inferior-Grade 027 eyes
SymptomaticConjunctival RednessBulbar-Inferior-Grade 40 eyes
SymptomaticConjunctival RednessBulbar-Superior- Grade 031 eyes
SymptomaticConjunctival RednessBulbar-Superior- Grade 157 eyes
SymptomaticConjunctival RednessBulbar-Superior- Grade 28 eyes
SymptomaticConjunctival RednessBulbar-Superior- Grade 30 eyes
SymptomaticConjunctival RednessBulbar-Superior- Grade 40 eyes
SymptomaticConjunctival RednessLimbal-Nasal- Grade 028 eyes
SymptomaticConjunctival RednessLimbal-Nasal- Grade 22 eyes
SymptomaticConjunctival RednessLimbal-Nasal- Grade 30 eyes
SymptomaticConjunctival RednessLimbal-Nasal- Grade 40 eyes
SymptomaticConjunctival RednessLimbal-Temporal- Grade 033 eyes
SymptomaticConjunctival RednessLimbal-Temporal- Grade 158 eyes
SymptomaticConjunctival RednessLimbal-Temporal- Grade 25 eyes
SymptomaticConjunctival RednessLimbal-Temporal- Grade 30 eyes
SymptomaticConjunctival RednessLimbal-Inferior- Grade 040 eyes
SymptomaticConjunctival RednessLimbal-Inferior- Grade 155 eyes
SymptomaticConjunctival RednessLimbal-Inferior- Grade 21 eyes
SymptomaticConjunctival RednessLimbal-Inferior- Grade 30 eyes
SymptomaticConjunctival RednessLimbal-Inferior- Grade 40 eyes
SymptomaticConjunctival RednessLimbal-Superior- Grade 046 eyes
SymptomaticConjunctival RednessLimbal-Superior- Grade 25 eyes
SymptomaticConjunctival RednessLimbal-Superior- Grade 30 eyes
SymptomaticConjunctival RednessLimbal-Superior- Grade 40 eyes
SymptomaticConjunctival RednessBulbar-Inferior-Grade 23 eyes
Secondary

Conjunctival Staining

Conjunctival staining was assessed for each eye by quadrant (Superior, Inferior, Nasal, Temporal) utilizing the following scale: Grade 0 = None (No conjunctival staining), Grade 1 = Trace (Scattered superficial punctate staining), Grade 2 = Mild (Regional or generalized punctate staining), Grade 3 = Moderate (Significant coalesced punctate staining), Grade 4 = Severe (Patch staining).

Time frame: 4-Week Follow-up

Population: All subjects dispensed a study lens.

ArmMeasureGroupValue (NUMBER)
AsymptomaticConjunctival StainingInferior-Grade 026 eyes
AsymptomaticConjunctival StainingTemporal- Grade 020 eyes
AsymptomaticConjunctival StainingInferior-Grade 19 eyes
AsymptomaticConjunctival StainingNasal- Grade 219 eyes
AsymptomaticConjunctival StainingInferior-Grade 219 eyes
AsymptomaticConjunctival StainingTemporal- Grade 119 eyes
AsymptomaticConjunctival StainingInferior-Grade 30 eyes
AsymptomaticConjunctival StainingNasal- Grade 017 eyes
AsymptomaticConjunctival StainingSuperior- Grade 028 eyes
AsymptomaticConjunctival StainingTemporal- Grade 215 eyes
AsymptomaticConjunctival StainingSuperior- Grade 118 eyes
AsymptomaticConjunctival StainingNasal- Grade 30 eyes
AsymptomaticConjunctival StainingSuperior- Grade 28 eyes
AsymptomaticConjunctival StainingTemporal- Grade 30 eyes
AsymptomaticConjunctival StainingSuperior- Grade 30 eyes
AsymptomaticConjunctival StainingNasal- Grade 118 eyes
SymptomaticConjunctival StainingSuperior- Grade 30 eyes
SymptomaticConjunctival StainingNasal- Grade 017 eyes
SymptomaticConjunctival StainingNasal- Grade 228 eyes
SymptomaticConjunctival StainingNasal- Grade 30 eyes
SymptomaticConjunctival StainingTemporal- Grade 029 eyes
SymptomaticConjunctival StainingTemporal- Grade 151 eyes
SymptomaticConjunctival StainingTemporal- Grade 216 eyes
SymptomaticConjunctival StainingTemporal- Grade 30 eyes
SymptomaticConjunctival StainingInferior-Grade 030 eyes
SymptomaticConjunctival StainingInferior-Grade 151 eyes
SymptomaticConjunctival StainingInferior-Grade 213 eyes
SymptomaticConjunctival StainingInferior-Grade 32 eyes
SymptomaticConjunctival StainingSuperior- Grade 050 eyes
SymptomaticConjunctival StainingSuperior- Grade 144 eyes
SymptomaticConjunctival StainingSuperior- Grade 22 eyes
SymptomaticConjunctival StainingNasal- Grade 151 eyes
Secondary

Corneal Staining

Corneal staining was assessed for each eye by region (Central, Superior, Inferior, Nasal, Temporal). Corneal staining type was evaluated using the following the scale: Grade 0 = None, Grade 1 = Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate, and Grade 4 = Patch (\>1mm). Corneal staining area was evaluated using the following the scale: Grade 0 = 0% of region covered, Grade 1 = 10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4 = 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered, Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered, and Grade 10 = 100% of region covered. The following scale was used in the grading of corneal staining depth: Grade 0 = None, Grade 0 = Superficial epithelial, Grade 2 = Full epithelial, and Grade 3 = Stromal glow.

Time frame: 4-Week Follow-up

Population: All subjects dispensed a study lens.

ArmMeasureGroupValue (NUMBER)
AsymptomaticCorneal StainingStaining- Area-Nasal-Grade 40 eyes
AsymptomaticCorneal StainingStaining Type- Central- Grade 11 eyes
AsymptomaticCorneal StainingStaining Type- Central- Grade 22 eyes
AsymptomaticCorneal StainingStaining Type- Central- Grade 30 eyes
AsymptomaticCorneal StainingStaining Type-Inferior - Grade 048 eyes
AsymptomaticCorneal StainingStaining Type-Inferior - Grade 15 eyes
AsymptomaticCorneal StainingStaining Type-Inferior - Grade 30 eyes
AsymptomaticCorneal StainingStaining Type-Nasal - Grade 049 eyes
AsymptomaticCorneal StainingStaining Type-Nasal - Grade 14 eyes
AsymptomaticCorneal StainingStaining Type-Nasal - Grade 21 eyes
AsymptomaticCorneal StainingStaining Type-Temporal-Grade 12 eyes
AsymptomaticCorneal StainingStaining Type-Temporal-Grade 21 eyes
AsymptomaticCorneal StainingStaining Type-Temporal-Grade 30 eyes
AsymptomaticCorneal StainingStaining Type- Superior- Grade 050 eyes
AsymptomaticCorneal StainingStaining Type- Superior- Grade 30 eyes
AsymptomaticCorneal StainingStaining-Depth-Inferior-Grade 048 eyes
AsymptomaticCorneal StainingStaining-Depth-Inferior-Grade 16 eyes
AsymptomaticCorneal StainingStaining-Depth-Inferior-Grade 20 eyes
AsymptomaticCorneal StainingStaining-Depth-Nasal-Grade 049 eyes
AsymptomaticCorneal StainingStaining-Depth-Nasal-Grade 15 eyes
AsymptomaticCorneal StainingStaining-Depth-Nasal-Grade 20 eyes
AsymptomaticCorneal StainingStaining-Depth-Temporal-Grade 051 eyes
AsymptomaticCorneal StainingStaining-Depth-Temporal-Grade 13 eyes
AsymptomaticCorneal StainingStaining-Depth-Temporal-Grade 20 eyes
AsymptomaticCorneal StainingStaining-Depth-Superior-Grade 050 eyes
AsymptomaticCorneal StainingStaining-Depth-Superior-Grade 14 eyes
AsymptomaticCorneal StainingStaining-Depth-Superior-Grade 20 eyes
AsymptomaticCorneal StainingStaining- Area- Central- Grade 21 eyes
AsymptomaticCorneal StainingStaining- Area-Nasal-Grade 30 eyes
AsymptomaticCorneal StainingStaining- Area-Nasal-Grade 50 eyes
AsymptomaticCorneal StainingStaining-Area-Superior-Grade 20 eyes
AsymptomaticCorneal StainingStaining Type-Inferior - Grade 21 eyes
AsymptomaticCorneal StainingStaining Type-Nasal - Grade 30 eyes
AsymptomaticCorneal StainingStaining Type-Temporal-Grade 051 eyes
AsymptomaticCorneal StainingStaining Type- Superior- Grade 14 eyes
AsymptomaticCorneal StainingStaining Type- Superior- Grade 20 eyes
AsymptomaticCorneal StainingStaining- Area- Central- Grade 051 eyes
AsymptomaticCorneal StainingStaining- Area- Central- Grade 11 eyes
AsymptomaticCorneal StainingStaining- Area- Central- Grade 31 eyes
AsymptomaticCorneal StainingStaining- Area- Central- Grade 40 eyes
AsymptomaticCorneal StainingStaining- Area- Central- Grade 50 eyes
AsymptomaticCorneal StainingStaining- Area- Central- Grade 60 eyes
AsymptomaticCorneal StainingStaining- Area- Inferior- Grade 048 eyes
AsymptomaticCorneal StainingStaining- Area- Inferior- Grade 13 eyes
AsymptomaticCorneal StainingStaining- Area- Inferior- Grade 20 eyes
AsymptomaticCorneal StainingStaining- Area- Inferior- Grade 33 eyes
AsymptomaticCorneal StainingStaining- Area- Inferior- Grade 40 eyes
AsymptomaticCorneal StainingStaining- Area- Inferior- Grade 50 eyes
AsymptomaticCorneal StainingStaining- Area- Inferior- Grade 60 eyes
AsymptomaticCorneal StainingStaining- Area-Nasal-Grade 049 eyes
AsymptomaticCorneal StainingStaining- Area-Nasal-Grade 21 eyes
AsymptomaticCorneal StainingStaining- Area-Nasal-Grade 14 eyes
AsymptomaticCorneal StainingStaining Type- Central- Grade 051 eyes
AsymptomaticCorneal StainingStaining- Area-Nasal-Grade 60 eyes
AsymptomaticCorneal StainingStaining-Area-Temporal-Grade 051 eyes
AsymptomaticCorneal StainingStaining-Area-Temporal-Grade 11 eyes
AsymptomaticCorneal StainingStaining-Area-Temporal-Grade 22 eyes
AsymptomaticCorneal StainingStaining-Area-Temporal-Grade 30 eyes
AsymptomaticCorneal StainingStaining-Area-Temporal-Grade 40 eyes
AsymptomaticCorneal StainingStaining-Area-Temporal-Grade 50 eyes
AsymptomaticCorneal StainingStaining-Area-Temporal-Grade 60 eyes
AsymptomaticCorneal StainingStaining-Area-Superior-Grade 050 eyes
AsymptomaticCorneal StainingStaining-Area-Superior-Grade 13 eyes
AsymptomaticCorneal StainingStaining-Area-Superior-Grade 30 eyes
AsymptomaticCorneal StainingStaining-Area-Superior-Grade 41 eyes
AsymptomaticCorneal StainingStaining-Area-Superior-Grade 50 eyes
AsymptomaticCorneal StainingStaining-Area-Superior-Grade 60 eyes
AsymptomaticCorneal StainingStaining-Depth-Central-Grade 051 eyes
AsymptomaticCorneal StainingStaining-Depth-Central-Grade 13 eyes
AsymptomaticCorneal StainingStaining-Depth-Central-Grade 20 eyes
SymptomaticCorneal StainingStaining- Area-Nasal-Grade 21 eyes
SymptomaticCorneal StainingStaining Type- Central- Grade 088 eyes
SymptomaticCorneal StainingStaining Type-Temporal-Grade 092 eyes
SymptomaticCorneal StainingStaining Type- Central- Grade 15 eyes
SymptomaticCorneal StainingStaining- Area-Nasal-Grade 30 eyes
SymptomaticCorneal StainingStaining Type- Central- Grade 23 eyes
SymptomaticCorneal StainingStaining-Depth-Central-Grade 20 eyes
SymptomaticCorneal StainingStaining Type- Central- Grade 30 eyes
SymptomaticCorneal StainingStaining Type- Superior- Grade 30 eyes
SymptomaticCorneal StainingStaining Type-Inferior - Grade 075 eyes
SymptomaticCorneal StainingStaining- Area-Nasal-Grade 40 eyes
SymptomaticCorneal StainingStaining Type-Inferior - Grade 117 eyes
SymptomaticCorneal StainingStaining- Area-Nasal-Grade 50 eyes
SymptomaticCorneal StainingStaining Type-Inferior - Grade 30 eyes
SymptomaticCorneal StainingStaining- Area- Central- Grade 22 eyes
SymptomaticCorneal StainingStaining Type-Nasal - Grade 092 eyes
SymptomaticCorneal StainingStaining-Area-Superior-Grade 089 eyes
SymptomaticCorneal StainingStaining Type-Nasal - Grade 12 eyes
SymptomaticCorneal StainingStaining- Area- Central- Grade 31 eyes
SymptomaticCorneal StainingStaining Type-Nasal - Grade 22 eyes
SymptomaticCorneal StainingStaining-Area-Superior-Grade 50 eyes
SymptomaticCorneal StainingStaining Type-Temporal-Grade 12 eyes
SymptomaticCorneal StainingStaining-Area-Superior-Grade 14 eyes
SymptomaticCorneal StainingStaining Type-Temporal-Grade 22 eyes
SymptomaticCorneal StainingStaining- Area- Central- Grade 50 eyes
SymptomaticCorneal StainingStaining Type-Temporal-Grade 30 eyes
SymptomaticCorneal StainingStaining-Area-Temporal-Grade 12 eyes
SymptomaticCorneal StainingStaining Type- Superior- Grade 088 eyes
SymptomaticCorneal StainingStaining Type- Superior- Grade 16 eyes
SymptomaticCorneal StainingStaining Type- Superior- Grade 22 eyes
SymptomaticCorneal StainingStaining- Area- Central- Grade 60 eyes
SymptomaticCorneal StainingStaining-Area-Superior-Grade 23 eyes
SymptomaticCorneal StainingStaining-Depth-Inferior-Grade 077 eyes
SymptomaticCorneal StainingStaining- Area- Inferior- Grade 076 eyes
SymptomaticCorneal StainingStaining-Depth-Inferior-Grade 119 eyes
SymptomaticCorneal StainingStaining-Area-Temporal-Grade 22 eyes
SymptomaticCorneal StainingStaining-Depth-Inferior-Grade 20 eyes
SymptomaticCorneal StainingStaining- Area- Inferior- Grade 110 eyes
SymptomaticCorneal StainingStaining-Depth-Nasal-Grade 093 eyes
SymptomaticCorneal StainingStaining-Depth-Central-Grade 089 eyes
SymptomaticCorneal StainingStaining-Depth-Nasal-Grade 13 eyes
SymptomaticCorneal StainingStaining- Area- Inferior- Grade 28 eyes
SymptomaticCorneal StainingStaining-Depth-Nasal-Grade 20 eyes
SymptomaticCorneal StainingStaining-Area-Temporal-Grade 30 eyes
SymptomaticCorneal StainingStaining-Depth-Temporal-Grade 093 eyes
SymptomaticCorneal StainingStaining- Area- Inferior- Grade 32 eyes
SymptomaticCorneal StainingStaining-Depth-Temporal-Grade 13 eyes
SymptomaticCorneal StainingStaining-Area-Superior-Grade 30 eyes
SymptomaticCorneal StainingStaining-Depth-Temporal-Grade 20 eyes
SymptomaticCorneal StainingStaining- Area- Inferior- Grade 40 eyes
SymptomaticCorneal StainingStaining-Depth-Superior-Grade 089 eyes
SymptomaticCorneal StainingStaining-Area-Temporal-Grade 40 eyes
SymptomaticCorneal StainingStaining-Depth-Superior-Grade 17 eyes
SymptomaticCorneal StainingStaining- Area- Inferior- Grade 50 eyes
SymptomaticCorneal StainingStaining-Depth-Superior-Grade 20 eyes
SymptomaticCorneal StainingStaining- Area- Central- Grade 089 eyes
SymptomaticCorneal StainingStaining- Area- Central- Grade 14 eyes
SymptomaticCorneal StainingStaining-Area-Superior-Grade 60 eyes
SymptomaticCorneal StainingStaining- Area- Central- Grade 40 eyes
SymptomaticCorneal StainingStaining- Area-Nasal-Grade 093 eyes
SymptomaticCorneal StainingStaining- Area- Inferior- Grade 60 eyes
SymptomaticCorneal StainingStaining-Area-Temporal-Grade 50 eyes
SymptomaticCorneal StainingStaining- Area-Nasal-Grade 60 eyes
SymptomaticCorneal StainingStaining-Area-Temporal-Grade 092 eyes
SymptomaticCorneal StainingStaining-Area-Superior-Grade 40 eyes
SymptomaticCorneal StainingStaining-Depth-Central-Grade 17 eyes
SymptomaticCorneal StainingStaining-Area-Temporal-Grade 60 eyes
SymptomaticCorneal StainingStaining Type-Inferior - Grade 24 eyes
SymptomaticCorneal StainingStaining- Area-Nasal-Grade 12 eyes
SymptomaticCorneal StainingStaining Type-Nasal - Grade 30 eyes
Secondary

Tear Film Lipid Layer Thickness

Tear film lipid layer thickness was measured for each eye using LipiView II. The Review Lipid Images screen provided numerical analysis of the measured lipid layer thickness in nanometers (nm) from 10 (thinnest) to 240 (thickest), with a precision of 1 nm and an accuracy of 10 nm.

Time frame: 4-Week Follow-up

Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.

ArmMeasureValue (MEAN)Dispersion
AsymptomaticTear Film Lipid Layer Thickness66.81 nmStandard Deviation 19.336
SymptomaticTear Film Lipid Layer Thickness63.00 nmStandard Deviation 16.208
Secondary

Tear Film Lipid Pattern

Tear film lipid pattern was recorded for each eye using the following categories: None, Open Meshwork, Closed (Tight Meshwork), Flow (Wave), Amorphous, Colors, and Other.

Time frame: 4-Week Follow-up

Population: All subjects that completed all study visits without a major protocol deviation.

ArmMeasureGroupValue (NUMBER)
AsymptomaticTear Film Lipid PatternClosed (Tight)18 eyes
AsymptomaticTear Film Lipid PatternAmorphous11 eyes
AsymptomaticTear Film Lipid PatternOpen Meshwork6 eyes
AsymptomaticTear Film Lipid PatternColors3 eyes
AsymptomaticTear Film Lipid PatternFlow (Wave)14 eyes
AsymptomaticTear Film Lipid PatternOthers0 eyes
AsymptomaticTear Film Lipid PatternNone0 eyes
SymptomaticTear Film Lipid PatternOthers0 eyes
SymptomaticTear Film Lipid PatternNone0 eyes
SymptomaticTear Film Lipid PatternOpen Meshwork24 eyes
SymptomaticTear Film Lipid PatternClosed (Tight)22 eyes
SymptomaticTear Film Lipid PatternFlow (Wave)28 eyes
SymptomaticTear Film Lipid PatternAmorphous15 eyes
SymptomaticTear Film Lipid PatternColors5 eyes
Secondary

Tear Film Stability

Non-invasive tear break-up time (NIBUT) was measured for each eye to indicate the stability of the tear film. NIBUT is measured as the time interval in seconds after the final blink to the first appearance of distortion in the reflected rings; or to the time that the participant has to blink due to discomfort. Three measurements were taken on each eye. The average NIBUT was reported for each group.

Time frame: 4-Week Follow-up

Population: All subjects who have successfully completed all visits and did not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hardlock.

ArmMeasureValue (MEAN)Dispersion
AsymptomaticTear Film Stability8.03 secondsStandard Deviation 3.846
SymptomaticTear Film Stability6.78 secondsStandard Deviation 4.327

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026